Skip to content
AiSeekAiSeek
Sign in
NewHealthReported 2026-10-09 06:35

Phase 3 study of deucrictibant for hereditary angioedema shows rapid symptom relief and resolution, published in The Lancet

Results from the RAPIDe-3 phase 3 trial show that oral deucrictibant IR (20 mg) achieved symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours for treating HAE attacks, with a well-tolerated safety profile. The study met all primary and secondary endpoints with high statistical significance across subgroups. NDA and MAA submissions are under regulatory review.

Why it matters. This advancement offers a potential first oral treatment option for hereditary angioedema, addressing unmet needs for rapid, convenient on-demand therapy in a rare but serious condition affecting thousands globally.

01

Evidence

  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    to complete symptom resolution (11.95 hours)
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    the consistent results from RAPIDe-3 across subgroups underscores the clinical relevance of antagonizing the bradykinin B2 receptor
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    While Pharvaris may elect to update such forward-looking statements at some point in the future
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    Pharvaris disclaims any obligation to do so
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    Deucrictibant IR showed a well-tolerated safety profile
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    Deucrictibant IR was well tolerated with no safety signals observed.
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    oral deucrictibant immediate-release (IR) capsule (20 mg)
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    RAPIDe-3 (NCT06343779) met its primary endpoint and all 11 secondary endpoints with high statistical significance.
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours)
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)
    View source
  • GGlobeNewswire public company newsCompany2026-10-09 06:35
    RAPIDe-3 (NCT06343779) met its primary endpoint and all 11 secondary endpoints with high statistical significance. Deucrictibant IR achieved End of Progression™1 (EoP) of attack symptoms, symptom relief, and complete symptom resolution significantly faster than placebo, with mos…
    View source